Telehealth Weight Loss/GLP-1 Prescribing: What Psychiatric NPs Can Do in Georgia

If you’re a psychiatrist or PMHNP watching the GLP-1 boom and wondering whether weight-loss prescribing fits into your practice, you’re not alone. The question isn’t just ‘Can I do this?’ — it’s ‘Should I? Is it worth the regulatory headache? And will it actually help my patients?’

Here’s the straight answer: Yes, psychiatric prescribers can (and increasingly do) prescribe GLP-1 medications for weight management — but the regulatory landscape varies dramatically by state, your provider type matters, and you need to understand both the clinical rationale and the compliance requirements before diving in.

This isn’t about chasing trendy revenue streams. It’s about recognizing that metabolic health and mental health are deeply connected, and for many of your patients — especially those dealing with medication-induced weight gain, treatment-resistant depression, or comorbid obesity — addressing weight through medications like semaglutide or liraglutide can be legitimate, integrated care.

Let’s break down what you actually need to know.

Why Psychiatrists Are Entering the Weight-Loss Space

The Clinical Overlap Is Real

If you’re a psychiatrist, you’re already managing metabolic side effects. Antipsychotics cause weight gain. SSRIs can too. You monitor glucose, lipids, and metabolic syndrome markers because you have to — it’s part of responsible psychiatric care.

So why wouldn’t you also treat the metabolic consequences of the medications you prescribe?

Dr. Elliott Lewis, a psychiatrist and obesity medicine specialist, frames it this way: ‘If we truly understand that metabolic and mental health systems are inseparable, then psychiatrists being involved in metabolic treatment makes complete sense.’ You’re not stepping outside your lane — you’re addressing the whole patient.

GLP-1s Have Mental Health Benefits Beyond Weight Loss

Here’s what’s getting buried in the Ozempic hype: GLP-1 receptor agonists may have direct effects on mental health, independent of weight loss.

Early research suggests these medications:

• Reduce inflammation (which is linked to depression)
• May improve mood and quality of life scores
• Could reduce cravings in substance use disorders and binge-eating patterns
• Show no increase in depression or suicidality risk (despite early media panic)

A 2025 meta-analysis in JAMA Psychiatry found no causal link between GLP-1 medications and suicidal ideation. In fact, treated groups showed slightly lower rates of depressive symptoms compared to placebo groups. Regulatory agencies (FDA and EMA) reviewed the data and reached the same conclusion.

For psychiatrists, this matters. You can feel confident that prescribing a GLP-1 for a patient struggling with obesity and depression isn’t destabilizing their mental health — and may actually help.

Your Patients Need This

Many psychiatric patients face medication-induced weight gain, metabolic syndrome, or obesity that exacerbates their mental health conditions. Primary care doctors are overwhelmed. Endocrinologists have 6-month waitlists. Telehealth ‘weight-loss clinics’ are popping up everywhere, but many lack any mental health expertise.

You’re uniquely positioned to provide integrated care: managing both the psychiatric medications and the metabolic consequences, all while monitoring for mental health changes that other prescribers might miss.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Scope of Practice: Can You Legally Prescribe GLP-1s?

For Psychiatrists (MD/DO): Yes, With Caveats

You have full prescriptive authority in all 50 states. There’s no special certification required to prescribe FDA-approved weight-loss medications like Wegovy (semaglutide), Saxenda (liraglutide), or phentermine.

But scope of practice isn’t just about legal authority — it’s about competency.

If you’re going to prescribe GLP-1s, you should:

• Understand obesity as a chronic disease (not just ‘calories in, calories out’)
• Know the contraindications, side effects, and monitoring requirements for these medications
• Be prepared to coordinate care with primary care or endocrinology when needed
• Document your rationale clearly (especially if you’re treating obesity in patients who aren’t also under your psychiatric care)

Consider Getting Obesity Medicine Board Certification

This isn’t required, but it’s becoming more common. The American Board of Obesity Medicine (ABOM) accepts physicians from any specialty, including psychiatry. The certification process involves:

• ~60 hours of obesity-related CME (covering physiology, pharmacotherapy, behavioral interventions)
• Passing a comprehensive exam

Many psychiatrists are pursuing this to legitimize their scope expansion and demonstrate formal competency in metabolic treatment. It also helps with insurer credentialing and answering the inevitable ‘Is this within your scope?’ questions from hospital committees or licensing boards.

State-Specific Rules Still Apply

Even though you can prescribe nationally as an MD, state medical boards can impose specific requirements for weight-loss prescribing. For example:

• Florida requires documented BMI ≥30 (or ≥27 with comorbidities), a comprehensive physical exam, written informed consent, and follow-ups at least every 3 months. Miss a quarterly follow-up and you’re out of compliance.
• New Jersey mandates a full workup (history, physical, labs, psychiatric screening) before prescribing, plus documentation that you’ve addressed or stabilized any psychiatric conditions.
• Virginia requires follow-up within 30 days of starting treatment, then monthly initially.

These aren’t suggestions — they’re enforceable board rules. Violate them and you risk disciplinary action.

For PMHNPs: It Depends Entirely on Your State

Nurse practitioners face a patchwork of state laws governing prescriptive authority. Here’s the breakdown:

Full Practice Authority (FPA) States (~24 states + DC):If you’re in a state like New York (after 3,600 hours), Illinois (after 4,000 hours + additional training), or Arizona, you can prescribe weight-loss medications independently — no physician oversight required.

Reduced/Restricted Practice States:In states like Texas, Florida, Pennsylvania, and California (until 2026), you must have a collaborative agreement or supervising physician to prescribe.

Here’s what that looks like in practice:

• Texas: You need a written Prescriptive Authority Agreement (PAA) with a Texas-licensed physician. The agreement must specify that you can prescribe weight-loss medications (including Schedule IV anorectics like phentermine). You’ll need monthly meetings with your collaborating physician and chart reviews.

• Florida: You need a supervising physician and a written protocol. Even if you have Florida’s ‘Autonomous APRN’ status (which excludes psychiatric NPs anyway), you cannot independently prescribe controlled substances for weight loss. GLP-1s (non-controlled) are fine with proper supervision.

• California: Until 2026, you need physician-approved standardized procedures. AB 890 is phasing in independence, but even then, California’s Corporate Practice of Medicine doctrine means you can’t own a weight-loss clinic — a physician must be the medical director.

Even in FPA States, Practical Barriers Exist

Here’s what nobody tells you: Even in states where NPs have full prescriptive authority, insurers and pharmacies sometimes require physician involvement for high-cost medications like GLP-1s.

Some independent NPs report that prior authorizations get denied or delayed unless a physician’s name is on the form. Compounding pharmacies may demand ‘physician oversight’ for semaglutide orders. This isn’t law — it’s policy — but it’s real, and it can slow down your practice.

Specialty Scope Considerations

You’re a psychiatric mental health nurse practitioner. Does prescribing weight-loss drugs fall within your specialty scope?

Technically, scope of practice is defined by competency and training, not just your certification specialty. If you’re treating a patient’s psychiatric condition and addressing medication-induced weight gain or comorbid obesity as part of holistic care, you’re on solid ground.

But if you’re advertising a standalone weight-loss clinic for the general public with no psychiatric component? That’s riskier. Some state nursing boards could argue you’re practicing outside your population focus.

The safe approach: Integrate weight management into psychiatric care (e.g., managing both depression and obesity in the same patient), pursue additional training in obesity medicine, and document your rationale clearly.

Telehealth Prescribing: Federal Green Light, State Red Lights

Here’s where it gets tricky.

Federally, the DEA extended COVID-era waivers allowing providers to prescribe controlled substances via telehealth without an initial in-person exam. That waiver runs through December 31, 2025 (and will likely be extended again).

So at the federal level, you’re good to go: You can prescribe phentermine (Schedule IV) or other controlled weight-loss medications via video visit.

But states can override federal rules.

State Telehealth Restrictions You Need to Know

Florida: State law prohibits prescribing controlled substances via telehealth except for specific exceptions: psychiatric treatment, inpatient/hospice care, or emergency addiction treatment.

Weight loss isn’t one of the exceptions. That means you cannot prescribe phentermine via telehealth to Florida patients, even though the DEA says it’s fine federally. You can prescribe GLP-1s (which aren’t controlled) via telehealth, as long as you meet Florida’s obesity treatment rules (quarterly follow-ups, documented exam, etc.).

Alabama: Requires an in-person exam before prescribing any controlled substance via telehealth. No exceptions for weight loss.

Other states (South Carolina, Idaho, New Jersey in some cases) have similar restrictions.

The bottom line: Check state law before prescribing controlled substances via telehealth. Federal waivers don’t preempt stricter state rules.

Establishing a Valid Patient Relationship via Telehealth

Most states now recognize that a video visit can establish a doctor-patient relationship equivalent to in-person care, as long as the standard of care is met.

But ‘standard of care’ for weight management means:

• Documenting height, weight, BMI (ask patients to weigh themselves or use recent primary care records)
• Taking a comprehensive history (medical, psychiatric, dietary, exercise habits)
• Performing a ‘visual exam’ via video (assessing general appearance, etc.)
• Ordering labs when appropriate (glucose, lipids, thyroid, liver function)
• Providing informed consent about risks and benefits

Some providers partner with local labs or ask patients to get a physical exam from their PCP to satisfy more stringent state requirements (like Florida’s ‘comprehensive physical exam’ rule).

Avoid the Async Trap

Don’t try to prescribe weight-loss medications through questionnaire-only platforms with no video visit.

In 2023, a Mississippi doctor had his license suspended for prescribing Ozempic via an instant-messaging platform with no audio or video consult. The state medical board called it a failure to establish a proper patient relationship.

Even if your state technically allows asynchronous telehealth, the standard of care for prescribing medications with significant metabolic effects demands at least a video consultation.

Reimbursement: Can You Actually Get Paid?

Insurance Coverage Is Improving Rapidly

Five years ago, weight-loss medications were mostly cash-pay. Not anymore.

GLP-1 receptor agonists (Wegovy, Saxenda, and soon Zepbound/Mounjaro for obesity) are now covered by many commercial insurers, though usually with prior authorization requirements:

• Documented BMI ≥30 (or ≥27 with comorbidities)
• Evidence of lifestyle intervention attempts (diet, exercise)
• Sometimes, mandatory participation in a weight management program

Medicare is about to change the game entirely. In late 2024, the Biden administration proposed allowing Medicare to cover anti-obesity medications. By early 2026, the policy is moving forward — Medicare Part D plans will begin covering GLP-1s for eligible beneficiaries.

This is huge. It opens weight-loss treatment to millions of seniors and removes the biggest barrier (cost) for many patients.

State Medicaid programs are also expanding coverage. Some already cover at least one GLP-1 for obesity; more will follow Medicare’s lead.

Billing for Weight Management Visits

For the clinical visit itself, you’ll use standard E/M codes (99202-99215 for outpatient visits) or psychiatric evaluation codes, depending on the scenario.

If you’re seeing a patient primarily for weight management (not a psychiatric follow-up), code it as an E/M visit with obesity (E66.x) as the primary diagnosis. Document the time spent on counseling, review of labs, medication management, and lifestyle recommendations to justify the level of service.

Telehealth parity laws in many states (California, New York, Illinois, Pennsylvania, and others) require that insurers reimburse telehealth visits at the same rate as in-person visits. For Medicare, telehealth mental health visits have permanent parity.

Psychiatrists vs. NPs: Reimbursement Differences

• Psychiatrists (MD/DO): Reimbursed at 100% of the physician fee schedule by Medicare and most commercial payers. A 20-minute med management visit might pay $100-$150 depending on region and code.

• PMHNPs: Typically reimbursed at 85% of the physician fee by Medicare. Some commercial payers reimburse NPs at 90-100%, depending on the contract.

Illinois Medicaid reimburses APRNs at 100% of physician rates for all services — a progressive policy that makes NP practice financially competitive.

In most states, the reimbursement gap is narrowing. And if you’re on a platform like Klarity that handles billing, the difference matters less — you’re paid per appointment, not per CPT code.

Prior Authorization: Expect It

Most insurers require prior authorization for GLP-1 medications. You’ll need to submit:

• Patient’s current BMI and weight history
• Documentation of comorbidities (diabetes, hypertension, sleep apnea, etc.)
• Evidence of prior weight-loss attempts (diet, exercise, behavioral therapy)
• Justification for why this medication is medically necessary

Some insurers also impose quantity limits (e.g., 30-day supply initially to monitor adherence) or step therapy (try older, cheaper drugs first).

Is it a hassle? Yes. But it’s manageable, especially if you’re working with a platform that has a prior auth team.

State-by-State Compliance Snapshot

The Business Case: Should You Add This to Your Practice?

Let’s talk numbers.

Patient Acquisition Cost Reality Check

If you tried to build a weight-loss practice from scratch using DIY marketing (SEO, Google Ads, directory listings), here’s what you’d actually spend:

• Google Ads for mental health or weight-loss keywords: $15-40+ per click. Most clicks don’t convert. Realistic cost per booked patient: $200-400+.
• SEO: Takes 6-12 months of consistent investment ($2,000-5,000/month for agency work) before you see meaningful patient flow.
• Psychology Today / Zocdoc: Monthly subscription fees ($30-100+) plus you compete with hundreds of other providers on the same page. Zocdoc charges per booking ($35-100+).
• Total monthly marketing spend for a solo provider: $3,000-5,000+ with no guarantee of results.

Now compare that to a platform model like Klarity:

• No upfront marketing costs
• No monthly subscription fees
• Pay per appointment — you only pay when a qualified patient books with you
• Pre-qualified patients already matched to your specialty and availability
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow

You control your schedule. You only pay when you see patients. That’s guaranteed ROI vs. gambling thousands of dollars a month on marketing channels that may or may not work.

Revenue Potential

A psychiatrist seeing 10 weight-loss patients per week at $150 per visit (insured follow-up) = $1,500/week or $6,000/month in additional revenue.

An PMHNP in an FPA state seeing 15 patients per week at $120 per visit = $1,800/week or $7,200/month.

If you’re integrating weight management into existing psychiatric care (managing both depression and obesity in the same patient), you’re adding value without adding much time — many of these visits are already happening; you’re just expanding the scope of care.

The Klarity Advantage

Here’s why joining a telehealth platform makes more sense than going solo:

1. Patient Flow Without Marketing Risk: Klarity handles patient acquisition, matching, and scheduling. You don’t burn cash on ads that don’t convert.

2. Compliance Support: State-specific protocols, EMR templates, and legal guidance built in. You’re not navigating Florida’s quarterly follow-up rules or Texas PAA requirements alone.

3. Insurance Credentialing: Klarity manages payer relationships and prior authorizations. You prescribe; they handle the paperwork.

4. Telehealth Infrastructure: HIPAA-compliant video platform, e-prescribing, patient communication tools — no separate software costs.

5. Flexibility: You set your availability. See 5 patients a week or 25. Scale up or down as your schedule allows.

For providers who want to expand into weight management without the overhead and risk of building a practice from scratch, a platform model removes the barriers entirely.

Practical Steps to Start Prescribing GLP-1s

If you’re ready to integrate weight management into your practice, here’s how to do it right:

1. Get Trained

• Take CME courses on obesity medicine (ABOM offers several)
• Review FDA prescribing information for GLP-1 agonists (Wegovy, Saxenda, Ozempic)
• Understand contraindications (history of pancreatitis, medullary thyroid cancer, etc.)
• Learn to manage side effects (nausea, GI upset, potential gallbladder issues)

2. Verify Your State’s Requirements

• Check your state medical/nursing board website for obesity prescribing rules
• Confirm telehealth prescribing laws (especially for controlled substances)
• If you’re an NP, ensure your collaborative agreement (if required) explicitly covers weight-loss medications

3. Set Up Compliance Protocols

• Create an intake form that calculates BMI and documents comorbidities
• Build a template for informed consent (covering risks, benefits, off-label use if applicable)
• Schedule follow-up appointments at required intervals (e.g., every 3 months for Florida)
• Integrate PDMP checks into your workflow (for controlled substances)

4. Coordinate Care

• Communicate with patients’ primary care providers (they need to know you’re prescribing weight-loss meds)
• Order baseline labs (glucose, A1C, lipids, liver function, thyroid) and monitor periodically
• Refer to endocrinology or cardiology when appropriate (e.g., uncontrolled diabetes, severe obesity with comorbidities)

5. Document Thoroughly

• Note BMI, weight, vitals at every visit
• Document lifestyle counseling (diet, exercise, behavioral changes)
• Record any side effects and how you addressed them
• Justify higher-level E/M codes with detailed notes (especially for insurance audits)

6. Join a Platform That Handles the Rest

Instead of figuring out marketing, credentialing, prior auths, and patient acquisition on your own, join Klarity Health.

You get:

• Qualified patient leads matched to your specialty
• No upfront costs or monthly fees — pay only per appointment
• Compliance support for every state you practice in
• Insurance credentialing and billing handled for you
• Built-in telehealth platform and e-prescribing

You focus on clinical care. Klarity handles everything else.

The Bottom Line: This Is Integrated Care, Not a Side Hustle

Prescribing GLP-1 medications for weight loss isn’t about jumping on a trend or chasing revenue. It’s about recognizing that metabolic and mental health are inseparable, and that many of your patients need help with both.

If you’re a psychiatrist dealing with medication-induced weight gain, or a PMHNP seeing patients with comorbid obesity and depression, you’re already doing metabolic psychiatry — you just might not call it that.

Adding GLP-1s to your toolkit is a natural extension of comprehensive care. With the right training, clear documentation, and attention to state-specific rules, it’s entirely within your scope.

The regulatory landscape is complex, yes. But providers who navigate it successfully are seeing real clinical outcomes and building sustainable practices.

And you don’t have to do it alone. Platforms like Klarity remove the marketing risk, handle the compliance headaches, and give you access to patients who need exactly what you offer: expert psychiatric care that doesn’t ignore the metabolic consequences of mental health treatment.

Ready to expand your practice without the overhead? Join Klarity Health’s provider network and start seeing patients who need integrated mental health and metabolic care — on your schedule, with none of the patient acquisition risk.

FAQ: GLP-1 Prescribing for Psychiatric Providers

Can psychiatrists legally prescribe GLP-1 medications for weight loss?

Yes. Psychiatrists (MD/DO) have full prescriptive authority in all 50 states and can prescribe FDA-approved weight-loss medications like Wegovy (semaglutide), Saxenda (liraglutide), or phentermine. However, you must follow state-specific obesity prescribing rules (e.g., Florida requires documented BMI ≥30, quarterly follow-ups, and written informed consent). Additional training in obesity medicine is recommended to ensure competency and may be required for hospital credentialing or insurer contracts.

Can PMHNPs prescribe weight-loss medications independently?

It depends on your state. In Full Practice Authority (FPA) states like New York (after 3,600 hours), Illinois (after 4,000 hours + training), or Arizona, PMHNPs can prescribe weight-loss medications independently. In restricted/collaborative states like Texas, Florida, Pennsylvania, and California (until 2026), you need a supervising physician and a written collaborative agreement that explicitly authorizes weight-loss prescribing. Even in FPA states, some insurers or pharmacies may require physician involvement for high-cost GLP-1s.

Do GLP-1 medications increase the risk of depression or suicidal ideation?

No. A 2025 meta-analysis in JAMA Psychiatry found no increase in depression or suicidality with GLP-1 medications versus placebo. The FDA and EMA reviewed the data and found no causal link. In fact, some studies show GLP-1-treated groups had slightly lower rates of depressive symptoms. Psychiatrists can prescribe these medications with confidence, though careful monitoring is always appropriate.

Can I prescribe phentermine via telehealth?

Federally, yes — the DEA extended COVID-era waivers allowing controlled substance prescribing via telehealth through December 31, 2025. But state law can override federal rules. Florida prohibits prescribing controlled substances via telehealth except for psychiatric treatment, inpatient/hospice care, or addiction emergencies (weight loss doesn’t qualify). Alabama requires an in-person exam. Check your state’s specific telehealth laws before prescribing controlled substances remotely. GLP-1s (which aren’t controlled) can be prescribed via telehealth in all states as long as you meet standard-of-care requirements.

What are the state-specific compliance requirements for weight-loss prescribing?

Requirements vary significantly by state:

• Florida: Requires documented BMI ≥30 (or ≥27 with comorbidities), a comprehensive physical exam, written informed consent, a state-mandated ‘Weight-Loss Consumer Bill of Rights,’ PDMP check for controlled substances, and follow-ups at least every 3 months.
• New Jersey: Requires a comprehensive workup (history, physical, labs, psychiatric screening), documentation that psychiatric issues are treated or stabilized, and integration of nutrition/exercise counseling.
• Virginia: Requires follow-up within 30 days of starting treatment, then monthly initially, plus a documented diet/exercise plan.
• Texas, California, Pennsylvania, New York, Illinois: No state-specific obesity prescribing rules beyond general standard of care, though NP collaboration requirements vary (see above).

Always check your state medical/nursing board website for current rules.

Will insurance cover GLP-1 medications for my patients?

Increasingly, yes. Many commercial insurers now cover FDA-approved GLP-1 weight-loss medications (Wegovy, Saxenda) with prior authorization. Requirements typically include: BMI ≥30 (or ≥27 with comorbidities), documentation of prior weight-loss attempts, and evidence of comprehensive weight management (diet, exercise, behavioral counseling). Medicare will begin covering anti-obesity medications in 2026 under new agreements with manufacturers. State Medicaid coverage varies but is expanding. Be prepared to submit detailed prior authorizations and justify medical necessity.

How much can I earn from weight-loss medication management?

A psychiatrist seeing 10 weight-loss patients per week at $150 per insured follow-up visit generates ~$6,000/month in additional revenue. An PMHNP in an FPA state seeing 15 patients per week at $120 per visit generates ~$7,200/month. These are conservative estimates assuming quarterly follow-ups (Florida’s minimum). Revenue scales with volume, but managing 20-30 weight-loss patients alongside your psychiatric caseload is realistic and financially sustainable. Platforms like Klarity remove patient acquisition costs and provide steady patient flow without upfront marketing spend.

Is it worth getting Obesity Medicine board certification?

It’s not required, but it’s increasingly valuable. The American Board of Obesity Medicine (ABOM) certification demonstrates formal competency in metabolic treatment, which can help with:

• Insurer credentialing (some payers prefer or require obesity certification for GLP-1 prescribing)
• Hospital/clinic privileges for weight management
• Legitimizing scope expansion (answers the ‘Is this within your scope?’ question)
• Patient trust and marketing differentiation

The certification requires ~60 hours of obesity-related CME and passing a comprehensive exam. Many psychiatrists pursuing this route report it strengthens their clinical knowledge and confidence significantly.

What’s the safest way to integrate weight management into psychiatric practice?

Start with patients who are already under your psychiatric care and have a clear clinical indication: medication-induced weight gain, comorbid obesity worsening mental health outcomes, or metabolic syndrome. Document thoroughly that you’re treating the whole patient, not running a standalone weight-loss clinic outside your specialty. Coordinate with their PCP, order appropriate labs, provide lifestyle counseling alongside medication, and follow your state’s compliance requirements. Consider joining a telehealth platform like Klarity that provides compliance support, pre-qualified patients, and infrastructure so you can focus on clinical care without the overhead of solo practice marketing and credentialing.

References

1. MedicalDirector Co. – ‘How Much Does a Collaborative Physician Cost for Weight Loss, Telehealth, and Medspas? (2025 Definitive Guide)’ (2025) – https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/

2. MedicalDirector Co. – ‘Florida Weight Loss Clinic and Telehealth Compliance Guide (2025)’ (Updated 2025) – https://www.medicaldirectorco.com/florida-weight-loss-clinic-and-telehealth-compliance-guide-2025/

3. MedicalDirector Co. – ‘Texas Weight Loss Clinic & Telehealth Compliance Guide (2025)’ (Updated 2025) – https://www.medicaldirectorco.com/texas-weight-loss-clinic-telehealth-compliance-guide/

4. Fla. Admin. Code R. 64B15-14.004 – ‘Standards for Prescription of Obesity Drugs’ (Effective Aug 8, 2022) – https://www.law.cornell.edu/regulations/florida/Fla-Admin-Code-Ann-R-64B15-14-004

5. Mondaq (Foley & Lardner) – ‘A Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs’ (July 24, 2023) – https://www.mondaq.com/unitedstates/healthcare/1447512/a-changing-regulatory-and-reimbursement-landscape-for-weight-loss-drugs

6. RxAgent.co – ‘Federal Permission, State Prohibition: The 2026 Telehealth Compliance Trap’ (Dec 16, 2025) – https://rxagent.co/blog/telehealth-compliance-trap

7. The Nurse Practitioner Journal – ’36th Annual APRN Legislative Update’ by Susanne J. Phillips (Jan 2024) – https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx

8. DrLewis.com (E. Lewis, MD) – ‘Should Psychiatrists Prescribe GLP-1s? An Evidence-Based Perspective’ (Jan 4, 2026) – https://drlewis.com/glp-1-medications-psychiatry/

9. DrLewis.com – ‘GLP-1 Medications & Mental Health: Facts vs Myths’ (Nov 26, 2025) – https://drlewis.com/glp-1-mental-health/

10. Axios – ‘COVID-era telehealth prescribing extended again’ (Nov 18, 2024) – https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall

11. Axios – ‘Trump announces Medicare coverage of weight-loss drugs’ (Nov 6, 2025) – https://www.axios.com/2025/11/06/medicare-coverage-weight-loss-glp1-ozempic-trump

12. TheraThink – ‘Insurance Reimbursement Rates for Psychiatrists [2026]’ (2026) – https://therathink.com/insurance-reimbursement-rates-for-psychiatrists/

13. Blue Cross Blue Shield TX – Provider Notice on GLP-1 Supply Limit (Oct 4, 2024) – https://www.bcbstx.com/provider/education/education/news/2024/10-04-24-pharmacy-supply-limit-glp1-obesity

Source:

• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=The%20answer%20is%20almost%20always,yes
• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=Nurse%20Practitioners%20
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Pennsylvania%20BON%20grants%20CRNPs%2C,more%20physicians%20to%20deliver%20healthcare
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Illinois%20Department%20of%20Financial,collaborative%20agreement%20following%20a%20TTP
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20DEA%20gave%20us%20the,evaluation%20at%20the%20federal%20level
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=Despite%20federal%20DEA%20waivers%20extending,traps%20for%20digital%20health%20providers
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=1.%20Florida%3A%20The%20%22No,for%20Stimulants
• https://www.mondaq.com/unitedstates/healthcare/1447512/a-changing-regulatory-and-reimbursement-landscape-for-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=You%20know%20these%20drugs,disorders%2C%20and%20possibly%20depression%20itself
• https://drlewis.com/glp-1-mental-health/#:~:text=Now%20let%E2%80%99s%20talk%20about%20potential,where%20things%20get%20really%20interesting